Navigation Links
Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
Date:9/17/2008

SAN DIEGO, Sept. 17 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD, President and CEO of Ardea Biosciences, will present at two upcoming investor conferences.

UBS Global Life Sciences Conference

Date: Wednesday, September 24, 2008

Time: 1:00 p.m. Eastern Time

Location: Grand Hyatt, New York

Webcast: http://www.ibb.ubs.com

Third Annual JMP Securities Healthcare Focus Conference

Date: Tuesday, October 7, 2008

Time: 2:00 p.m. Eastern Time

Location: Le Parker Meridian, New York

Webcast: http://www.ljfevents.com/jmp/CompanyReg.htm

About Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 clinical trial and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
4. Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference
5. Ardea Biosciences Announces $40 Million Private Placement
6. Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections
7. Ardea Biosciences Establishes Scientific Advisory Board for HIV Program
8. Ardea Biosciences to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference
9. Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program
10. Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego
11. Ardea to Present at Cowen and Companys 28th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Ill. , May 23, 2013 Z ... providing value-added ingredients to a variety of industries, announced ... in a panel discussion at this year,s National Restaurant ... 20-21, 2013, on behalf of the Research Chefs Association.  ... for Restaurants: The Good, the Bad and the Ugly," ...
(Date:5/23/2013)... , May 23, 2013 Pressure BioSciences, Inc. ... the Company will host a teleconference to discuss its ... business update. The teleconference information is provided below: ... Eastern Daylight Time (EDT) Dial-in: (800) 875-3456 ... 607-2001 (Int,l) Passcode: VS22823 For those unable ...
(Date:5/23/2013)... 2013 Pusan National University Yangsan Hospital, ... and contract research company focused on research and ... today a publication reporting the induction of functional ... and immunotherapeutic vaccinia JX-594 (pexastimogene devacirepvec; Jennerex Inc.). ... the May 15 th , 2013 issue of ...
(Date:5/23/2013)... Bed bugs already cost Alton Housing Authority thousands. And as ... from kmov.com suggested that the said office might need to ... be of help, My Cleaning Products gave tips how to ... service. , The report, which was posted on May ... $35,000 for bed bug elimination, My Cleaning Products shared. ...
Breaking Biology Technology:Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 2Z Trim's Chef Erin Ryan sits on Expert Panel at NRA Show 3Pressure BioSciences, Inc. to Discuss First Quarter 2013 Financial Results and Provide Business Update 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 2Pusan National University Announces Science Translational Medicine Publication Highlighting Landmark Demonstration of Functional Anti-Cancer Antibody Induction in Patients Following JX-594 Treatment 3Bed Bug Exterminator Service Could Cost AHA $250K, My Cleaning Products Gives Tips How to Save Apartments from Costly Bed Bug Treatment 2
... 2 Accera, Inc., a biotechnology ... (CNS) diseases, today launched Axona(TM) in the United ... first-in-class medical food for the clinical dietary management ... Dispensed by prescription, it targets the metabolic deficiencies ...
... /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... new Senior Secured Term Loan and Revolving Credit Facility. ... agent and lender for both the Term Loan and ... draw secured term loan facility of up to $10 ...
... Inc.,(Nasdaq: BNVI ) today announced the online ... Menerba(TM) (formerly MF101) is,well tolerated, safe and effective for ... associated with menopause. , The ... safety and,efficacy of two doses of Menerba versus placebo. ...
Cached Biology Technology:Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 2Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 3Video: Accera Launches Axona(TM), First Medical Food Therapy to Help Manage Mild-to-Moderate Alzheimer's Disease 4Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 2Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 3Bionovo Announces Publication of Positive Phase 2 Trial Results for Menerba(TM) 4
(Date:5/24/2013)... the immune system to combat metastatic cancer , ... destruction by the immune system. Stimulation of the immune ... are many factors that cause the immune system to ... that function to suppress the immune system response. In ... , researchers led by Ronald Levy at Stanford University ...
(Date:5/24/2013)... microRNAs (miRNAs) and other non-coding RNAs are small ... proteins. In recent years they have emerged as ... establish tissue origin for cancers of unknown primary ... for disease, but clinically tractable, diagnostic methods for ... currently available. In this issue of the ...
(Date:5/24/2013)... medication against Alzheimer,s disease, scientists have focused among other ... (A-beta). After all, it is the accumulation of A-beta that ... Starting point for the formation of A-beta is APP. Alessia ... unravel the function of APPL the fruit-fly version of ... , Alessia Soldano (VIB/KU Leuven): "We have discovered that APPL ...
Breaking Biology News(10 mins):JCI early table of contents for May 24, 2013 2JCI early table of contents for May 24, 2013 3JCI early table of contents for May 24, 2013 4JCI early table of contents for May 24, 2013 5JCI early table of contents for May 24, 2013 6JCI early table of contents for May 24, 2013 7JCI early table of contents for May 24, 2013 8A new strategy required in the search for Alzheimer's drugs? 2
... and scientific experts propose a global framework for the ... including further clinical testing In Australia. The South-Pacific ... anxiety but is restricted in some countries. Leading ... of Melbourne, Australia; Professor Rolf Teschke from Wolfgang Goethe-University, ...
... have made a significant discovery about the nature of ... Tanner, BDS, Ph.D., identified a new pathogen connected to ... wiggsiae , was present in the mouths of children ... such as Streptococcus mutans were not detected. ...
... especially for the excellence of its peacekeepers and ice ... to help countries elsewhere brace for drought, flood and ... year horizon. Within a single generation, recent studies ... by an estimated 40%, with one-third of humanity having ...
Cached Biology News:Experts propose global guidelines for safe use of Kava and new Australian study 2Forsyth team gains new insight on childhood dental disease 2Canada's role grows amid looming world water shortages in some places, more flooding in others 2Canada's role grows amid looming world water shortages in some places, more flooding in others 3Canada's role grows amid looming world water shortages in some places, more flooding in others 4Canada's role grows amid looming world water shortages in some places, more flooding in others 5Canada's role grows amid looming world water shortages in some places, more flooding in others 6Canada's role grows amid looming world water shortages in some places, more flooding in others 7
Rabbit anti-NFkB p105/p50 (Ser529) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
ABCA1 Immunogen: Mouse ABCA1-expressing HeLa stable transfectants. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Purified Mouse anti-Hu Actopaxin (pS8) Storage Temperature: Refrigerate(2 to 8C)...
Blank Calibration Particles, 3.0-3.4 mu m 5 ml...
Biology Products: